GlassScriptPhysician profile
Paul Michael Armistead
NPI 1235221524
$9,346.74
in general payments reported to CMS, 2019-2025
11 companies · $646 in 2025
The $646 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $8,701 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,810 · Food and Beverage: $2,220 · Travel and Lodging: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,810.00 |
| Food and Beverage | $2,219.80 |
| Travel and Lodging | $316.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $7,299.07 | 2024-2025 | Yescarta |
| National Marrow Donor Program | $986.49 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $234.34 | 2025 | Reblozyl |
| Sanofi-Aventis U.S. LLC | $204.68 | 2024-2025 | |
| Sobi, INC | $132.08 | 2025 | |
| Janssen Scientific Affairs, LLC | $125.20 | 2024 | Talvey, Tecvayli |
| Biolinerx USA, INC. | $97.88 | 2024 | Aphexda |
| Legend Biotech USA INC. | $95.99 | 2024 | Carvykti |
| Autolus INC | $81.12 | 2025 | |
| Incyte Corporation | $64.72 | 2025 | Jakafi, Niktimvo, Pemazyre |
| Genetix Biotherapeutics INC | $25.17 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Armistead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.